# US 2026/0076986 A1 · A combination of scyllo-inositol and flavones > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2026/0076986 A1 - Document ID: US20260076986A1 - Status: Published application - Kind: A1 - Application number: 19/109,142 - Filed: 2023-09-01 - Published: 2026-03-19 - Earliest claimed: 2022-09-07 - Assignees: Eirgen Pharma Ltd. - Applicants: Eirgen Pharma, Ltd. - Inventors: Phillip FROST; Antonio CRUZ; John K. CHOE; Jane H. HSIAO - Web page: https://patentgrep.com/patent/US20260076986A1 ## CPC - A61K 31/047: having two or more hydroxy groups, e.g. sorbitol - A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms - A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} - A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines} - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - C07K 16/18: against material from animals or humans - A61K 2039/545: {characterised by the dose, timing or administration schedule} - C07K 2317/21: from primates, e.g. man - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the flavone apigenin to support cognitive health in a subject that takes the product or combination product. The invention relates to compositions comprising scyllo-inositol alone or in combination with other agents including but not limited to a flavone or other substance that upregulates or prevents the downregulation of aquaporin 4 channels. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system. ## Claims ### Claim 1 A combination of (i) a first compound selected from an inositol or a pharmaceutically acceptable isomer or salt thereof and (ii) a second compound selected from a molecule that upregulates aquaporin 4. ### Claim 2 (depends on 1) The combination according to claim 1 wherein the first compound is selected from scyllo-inositol or other active 1,2,3,4,5,6-cyclohexanehexol and the second compound is selected from the group consisting of molecule flavone. ### Claim 3 (depends on 2) The combination according to claim 2 wherein the first compound is selected from scyllo-inositol and the second compound is selected from apigenin. ### Claim at position 4 4-5. (canceled) ### Claim 6 A dosage form comprising a combination of (i) a first compound selected from an inositol or a pharmaceutically acceptable isomer or salt thereof and (ii) a second compound selected from a flavone. ### Claim 7 (depends on 6) The dosage form according to claim 6 wherein the first compound is selected from scyllo-inositol or other active 1,2,3,4,5,6-cyclohexanehexol and the second compound is selected from apigenin. ### Claim 8 (depends on 7) The dosage form according to claim 7 wherein the first compound is selected from scyllo-inositol. ### Claim 9 (depends on 8) The dosage form according to claim 8 wherein in the form of a solid, oral dosage form. ### Claim 10 (depends on 9) The dosage form according to claim 9 wherein the dose of scyllo-inositol is about 75 to 150 mgs once or twice daily (BID) and the dose of apigenin is about 60-150 mgs per day. ### Claim 11 (depends on 6) The dosage form according to claim 6 wherein said dosage form is in the form of a capsule or tablet. ### Claim 12 (depends on 11) The dosage form according to claim 11 in the form of a tablet comprising an immediate release formulation of scyllo-inositol and an immediate release formulation of apigenin. ### Claim 13 (depends on 11) The dosage form according to claim 11 in the form of a tablet comprising an immediate release formulation of scyllo-inositol and an extended release formulation of apigenin. ### Claim 14 A method of treating a subject having an MMSE score in the range of 22-26 with a pharmaceutically effective amount of scyllo-inositol. ### Claim 15 (depends on 14) The method according to claim 14 wherein the subject has Alzheimer's disease. ### Claim 16 (depends on 14) The method according to claim 14 wherein the pharmaceutically effective amount of scyllo-inositol is about 250 mgs BID per day. ### Claim at position 16 17-30. (canceled) ### Claim 31 A method of supporting cognitive health comprising the administration of a nutraceutically effective amount of a composition comprising scyllo-inositol and apigenin. ### Claim 32 (depends on 31) The method according to claim 31 comprising providing the composition comprising scyllo-inositol and apigenin to subjects over the age of fifty at risk of accumulation of amyloid beta. ### Claim 33 (depends on 31) The method according to claim 31 wherein the subjects exhibit early signs of memory loss. ### Claim 34 (canceled)